Table 1.
Characteristics between the training set and the validation set
| Characteristics | All Patients n = 2205 (%) |
Training n = 1543 (%) |
Validation n = 662 (%) |
P value |
|---|---|---|---|---|
| Age (years) | ||||
| Median | 60 | 59 | 61 | |
| ≤ 60 | 1135 (51.5) | 814 (52.8) | 321 (48.5) | 0.066 |
| > 60 | 1070 (48.5) | 729 (47.2) | 341 (51.5) | |
| Race | ||||
| White | 1691 (76.7) | 1165 (75.5) | 526 (79.5) | 0.103 |
| Black | 364 (16.5) | 271 (17.6) | 93 (14.0) | |
| Othersa | 150 (6.8) | 107 (6.9) | 43 (6.5) | |
| Marital status | ||||
| Unmarried | 959 (43.5) | 670 (43.4) | 289 (43.6) | 0.750 |
| Married | 1173 (53.2) | 819 (53.1) | 354 (53.5) | |
| Unknown | 73 (3.3) | 54 (3.5) | 19 (2.9) | |
| Grade | ||||
| I | 103 (4.7) | 67 (4.4) | 36 (5.4) | 0.666 |
| II | 299 (13.6) | 207 (13.4) | 92 (13.9) | |
| III | 1701 (77.1) | 1199 (77.7) | 502 (75.8) | |
| IV | 102 (4.6) | 70 (4.5) | 32 (4.9) | |
| Laterality | ||||
| Right | 1129 (51.2) | 777 (50.4) | 352 (53.2) | 0.225 |
| Left | 1076 (48.8) | 766 (49.6) | 310 (46.8) | |
| ER status | ||||
| Negative | 1803 (81.8) | 1265 (82.0) | 538 (81.3) | 0.691 |
| Positive | 402 (18.2) | 278 (18.0) | 124 (18.7) | |
| PR status | ||||
| Negative | 1919 (87.0) | 1342 (87.0) | 577 (87.2) | 0.905 |
| Positive | 286 (13.0) | 201 (13.0) | 85 (12.8) | |
| HER-2 status | ||||
| Negative | 1091 (49.5) | 751 (48.7) | 340 (51.4) | 0.155 |
| Positive | 76 (3.4) | 60 (3.9) | 16 (2.4) | |
| Unknown | 1038 (47.1) | 732 (47.4) | 306 (46.2) | |
| Tumor size | ||||
| ≤ 2 cm | 572 (25.9) | 399 (25.9) | 173 (26.1) | 0.976 |
| > 2 cm and ≤ 5 cm | 1157 (52.5) | 812 (52.6) | 345 (52.1) | |
| > 5 cm | 476 (21.6) | 332 (21.5) | 144 (21.8) | |
| Regional lymph nodes | ||||
| Negative | 1659 (75.2) | 1164 (75.4) | 495 (74.8) | 0.741 |
| Positive | 546 (24.8) | 379 (24.6) | 167 (25.2) | |
ER Estrogen receptor, PR Progesterone receptor, HER-2 Human epidermal growth factor receptor-2
aIncludes: American Indian, native Alaskan and Asian, Pacific Islander